Skip to main
GUTS
GUTS logo

GUTS Stock Forecast & Price Target

GUTS Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Fractyl Health Inc. is strategically positioned within the metabolic therapeutics sector, as evidenced by the substantial 587% increase in prescriptions for GLP-1 drugs aimed at treating obesity from 2019 to 2024, highlighting a growing market demand. The company's focus on developing disease-modifying therapies, rather than merely managing symptoms, aligns well with this increasing recognition of effective metabolic disease treatments. Furthermore, Fractyl Health's current manufacturing capabilities are expected to adequately support the upcoming first-in-human clinical trial, with the potential for scalable growth as the program advances, reinforcing a strong operational foundation for future expansion.

Bears say

Fractyl Health Inc has shown improvements in clinical outcomes, such as a reduction in HbA1c levels from 9.6% to 7% and a decrease in fat mass, suggesting some initial success in its therapeutic approach. However, the company faces significant challenges with cash burn, particularly as it scales development and commercial programs, which could strain its financial resources unless offset by partnership revenues. The financial outlook remains precarious as these increasing expenditures may jeopardize operational sustainability and long-term growth potential.

GUTS has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Fractyl Health Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Fractyl Health Inc (GUTS) Forecast

Analysts have given GUTS a Strong Buy based on their latest research and market trends.

According to 4 analysts, GUTS has a Strong Buy consensus rating as of Nov 4, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6.90, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6.90, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Fractyl Health Inc (GUTS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.